Clinical trial
A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD
NCT02777931 is registered in ClinicalTrials.gov with Aevi Genomic Medicine, LLC, a Cerecor company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- June 30, 2016
- Completion date
- February 17, 2017
- Enrollment
- 101 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.